BRCA1 and melanoma: These inhibitors have been successfully used in homologous-recombination deficient cancers that include breast, ovarian, and prostate carcinomas, and, while preclinical data was promising for the use of Olaparib in melanoma, a case study of a patient with BRCA1-deficient metastatic AM derived 4 months of stable disease on Olaparib [56].